Kiniksa Pharmaceuticals International PLC
KNSA
Company Profile
Business description
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Contact
23 Old Bond Street
Floor 3
LondonW1S 4PZ
GBRT: +44 7814319100
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
315
Stocks News & Analysis
stocks
Perplexing buyback from overvalued ASX share
Earnings continue to grow but investor expectations are too high.
stocks
Most popular shares in SMSFs
With data showing the continued rise of SMSFs, we explore the top stock picks of individual investors
stocks
Will China strong arm BHP into lower iron ore prices?
Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,208.50 | 9.00 | -0.10% |
| CAC 40 | 7,898.18 | 36.08 | -0.45% |
| DAX 40 | 24,142.95 | 244.98 | -1.00% |
| Dow JONES (US) | 45,534.48 | 533.10 | -1.16% |
| FTSE 100 | 9,423.51 | 19.36 | -0.21% |
| HKSE | 25,441.35 | 448.13 | -1.73% |
| NASDAQ | 22,278.76 | 415.85 | -1.83% |
| Nikkei 225 | 46,847.32 | 1,733.12 | -3.57% |
| NZX 50 Index | 13,276.99 | 74.93 | -0.56% |
| S&P 500 | 6,570.22 | 84.50 | -1.27% |
| S&P/ASX 200 | 8,899.40 | 10.30 | -0.12% |
| SSE Composite Index | 3,865.23 | 24.27 | -0.62% |